We develop biparatopic antibodies as best-in-class therapies in oncology and autoimmunity. In oncology, we develop biparatopic ADCs against targets challenging to address with classical ADCs; in autoimmunity, we drive effector-independent combinatorial immunomodulation with checkpoint agonism as a foundation. Versant and NEA are our co-lead investors, and we have an oncology-focused co-development partnership with Pierre Fabre. First IND targeted 2027.

Tuesday, May 5, 13:30 - 13:45, room Singapore